Senti Bio announces first patient dosed in clinical trial of SN301A

Senti Bio (SNTI)sciences announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics. SN301A utilizes the anti-GPC3 + crIL-15 SENTI-301A Gene Circuit developed by Senti Bio and refers to the chimeric antigen receptor natural killer product candidate manufactured by Celest in China. Through this collaboration, Celest is leading clinical development, operations and manufacturing of SN301A with technical, strategic and clinical input from Senti Bio. The clinical trial is designed to evaluate safety, pharmacokinetics and preliminary anti-tumor activity of SN301A and will include patients with advanced glypican 3-expressing HCC across multiple dose cohorts. The study endpoints include safety assessments for adverse events and dose limiting toxicities, as well as efficacy analyses using standard response criteria for liver cancer.